Weiyong Sun

Money Moves

Said the Roche pact fits a strategy of taking on more development risk for more future profit

Roche agreed on Oct. 19 to pay Hansoh Pharmaceutical $400 million upfront, plus $110 million a year later, for a portfolio of antibody-drug conjugates: cancer drugs that carry a toxin straight to tumor cells. Hansoh could collect more than $15 billion in milestones if the programs clear development, regulatory and sales hurdles.

Updated Oct 30